Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VaccObFlu: Influvac Immunogenicity and Safety in People with Obesity
2025-522698-13-00Phase 4Authorised
- Sponsor
- Region Stockholm
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of influenza vaccine in influenza, obesity and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Region Stockholm. Primary endpoints: Hemagglutinin inhibition assay geometric mean titers, Proportion achieving protective HAI titer ≥40 and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
influenza vaccine
03
Conditions
influenzaobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-522698-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522698-13-00.